High doses of a helper-dependent adenoviral vector yield supraphysiological levels of α1-antitrypsin with negligible toxicity

Núria Morral, Robin J. Parks, Heshan Zhou, Claire Langston, Gudrun Schiedner, Janet Quinones, Frank L. Graham, Stefan Kochanek, Arthur L. Beaudet

Research output: Contribution to journalArticle

223 Scopus citations

Abstract

Optimal gene therapy for many disorders will require efficient transfer to cells in vivo, high-level and long-term expression, and tissue-specific regulation, all in the absence of significant toxicity or inflammatory responses. While recombinant adenoviral vectors are efficient for gene transfer to hepatocytes, their usefulness is limited by short duration of expression related, at least in part, to immune responses to viral proteins and by a low capacity for foreign DNA. A number of systems have been developed for producing adenoviral vectors devoid of all viral coding sequences. Using AdSTK109, a vector lacking all viral coding sequences and carrying the complete human α1-antitrypsin (hAAT) genomic DNA locus, we have demonstrated sustained expression for longer than 10 months in mice. Utilizing high doses of this vector for hepatic gene transfer in mice, we find that supraphysiological levels of hAAT can be achieved without hepatotoxicity.

Original languageEnglish (US)
Pages (from-to)2709-2716
Number of pages8
JournalHuman Gene Therapy
Volume9
Issue number18
DOIs
StatePublished - Dec 10 1998
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'High doses of a helper-dependent adenoviral vector yield supraphysiological levels of α<sub>1</sub>-antitrypsin with negligible toxicity'. Together they form a unique fingerprint.

  • Cite this

    Morral, N., Parks, R. J., Zhou, H., Langston, C., Schiedner, G., Quinones, J., Graham, F. L., Kochanek, S., & Beaudet, A. L. (1998). High doses of a helper-dependent adenoviral vector yield supraphysiological levels of α1-antitrypsin with negligible toxicity. Human Gene Therapy, 9(18), 2709-2716. https://doi.org/10.1089/hum.1998.9.18-2709